The EMBL Ventures-backed immunotherapy developer floated in an underpriced offering and received $20m in a private placement from NEA.
US-based monoclonal antibody developer Arsanis has gone public in a $40m initial public offering that provided exits for research institute European Molecular Biology Laboratory’s investment arm EMBL Ventures.
The company issued 4 million shares on the Nasdaq Global Market priced at $10 each, well below the IPO’s $15 to $17 range. A fund affiliated with venture capital firm New Enterprise Associates (NEA) agreed to buy another $20m of shares through a private placement.
Arsanis is developing monoclonal antibody-based…
